VIVUS

VVUS NASDAQ
3.400
+0.020
+0.59%
休市 16:00 07/19 EDT
开盘
3.380
昨收
3.380
最高
3.420
最低
3.370
成交量
1.05万
成交均量(3M)
2.88万
52周最高
7.48
52周最低
2.150
换手率
0.10%
市值
3,616.64万
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供VIVUS VVUS股票价格,VIVUS股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.
展开 >

最近浏览

名称
价格
涨跌幅